IMPACT aimed to investigate how the virus affects the immune system and how people with risks for blood cancer may respond to COVID-19 and its emerging vaccines.
The IMPACT study is an affiliate study of the PROMISE and PCROWD Studies. We analyze blood samples for up to one year to learn how COVID-19 exposure affects the immune system. All participants enrolled in IMPACT will receive a free antibody test to determine if they have been exposed to the virus that causes COVID-19.
The IMPACT Study is now closed and in its follow-up stage. If you are eligible, here are two affiliate studies you can join:
Already enrolled? PROMISE Dashboard Login / PCROWD Dashboard Login
Not enrolled? Both studies are welcoming new participants.
1. Join as a PROMISE Study participant
The PROMISE Study is for healthy people with risks for multiple myeloma but who do not have the early warning signs (called precursor conditions.)
Who can join?
-
Black or African American Individuals age 40 - 75 years
– And / Or –
-
Close family members of anyone with multiple myeloma OR or a precursor condition, also 40 - 75 years of age.
Close family members are people of any race who have a parent, sibling, or child with:
Multiple myeloma OR one these related conditions:
2. Join as a PCROWD Study participant
For anyone, age 18+, who has been diagnosed with a precursor condition for multiple myeloma.
ABOUT THIS STUDY
-
We study how the immune system responds to COVID-19 and the long-term impact of the virus in patients with precursor conditions and healthy individuals. The goals of IMPACT are:
-
To compare COVID-19 antibody levels and immune cell changes in patients with precursor conditions to those without precursor conditions.
-
To identify the people most at risk for long-term symptoms and immune complications after infection to COVID-19.
THE IMPORTANCE
The coronavirus disease, called COVID-19, continues to have a serious impact on millions of people, including people with or at risk for cancer. It is important to learn how COVID-19 will impact people with risks for blood cancer.
We Seek to Learn Answers to Questions Like These:
-
Do people who have risks for blood cancer also have greater risks for COVID-19?
-
If so, is there a COVID-19 treatment that would help people with cancer risks to protect their long-term health?
-
Who is most at risk for long-term symptoms and immune complications after infection with COVID-19?
-
Will precursor conditions make future COVID-19 vaccines more or less effective?
-
Do precursor patients who have recovered from COVID-19 have COVID-19 antibodies?
-
Are these patients who have recovered from COVID-19 protected from re-infection? If so, for how long?